D
Overview
Digital Biology operates as a data lab for AI-driven drug design. It labels protein designs with human-relevant functional data at library scale, enabling millions of designs to be tested in mammalian systems. The screening engine measures binding, developability, and tissue-level responses for antibodies, multispecifics, and custom biologics. The company aims to accelerate AI-enabled drug engineering by delivering scalable, actionable data that links design features to real-world biology, setting it apart from purely computational or small-scale approaches.
Work here?Claim your company
Simplify's take
What believers are saying
- The website updated October 4, 2026, signaling active product development.
- Bill & Melinda Gates Foundation backed the platform with $4,327,073.
- Lux Capital and Wyss Institute investors validate a deep-science capital base.
What critics are saying
- No public funding has closed since the October 2022 Gates grant.
- Caplight shows only 17 employees, limiting throughput and sales coverage.
- Chai Discovery and Aureka crowd the 2026 AI-biology market, compressing differentiation.
What makes Digital Biology unique
- Digital Biology labels protein designs with human-relevant functional data at scale.
- Its mammalian screening engine measures binding, developability, and tissue-level response.
- Watertown team targets protein engineering, not generic wet-lab automation.
Help us improve and share your feedback! Did you find this helpful?